Human TP63(Tumor Protein P63) ELISA Kit

Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.094 ng/ml

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tumor Protein P63 (TP63) in Tissue homogenates, cell lysates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tumor Protein P63 (TP63) in Tissue homogenates, cell lysates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tumor Protein P63 (TP63) in Tissue homogenates, cell lysates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tumor Protein P63 (TP63) in Tissue homogenates, cell lysates and other biological fluids.

Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Tumor Protein P63 (TP63) in samples from Tissue homogenates, cell lysates and other biological fluids. with no significant corss-reactivity with analogues from other species.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Tumor Protein P63 (TP63) in Tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Tumor Protein P63 (TP63) in Tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Tumor Protein P63 (TP63) in Tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Tumor Protein P63 (TP63) in Tissue homogenates and other biological fluids.

Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Mouse Tumor Protein P63 (TP63) in samples from Tissue homogenates and other biological fluids. with no significant corss-reactivity with analogues from other species.

Description: A sandwich ELISA kit for detection of Tumor Protein P63 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Description: A sandwich ELISA kit for quantitative measurement of Human TP63 (Tumor Protein p63) in samples from Serum, Plasma, Cell supernatant

Description: A sandwich ELISA kit for detection of Tumor Protein P63 from Mouse in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Description: Recombinant Human Tumor Protein P63 expressed in: chemical synthesis

Description: A sandwich CLIA kit for quantitative measurement of Human TP63 (Tumor Protein p63) in samples from Serum, Plasma, Cell supernatant

Description: A Mouse monoclonal antibody against Human Tumor Protein P63 (TP63)

Description: A Rabbit polyclonal antibody against Human Tumor Protein P63 (TP63)

Description: A Mouse monoclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with APC.

Description: A Mouse monoclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with Biotin.

Description: A Mouse monoclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with Cy3.

Description: A Mouse monoclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with FITC.

Description: A Mouse monoclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with HRP.

Description: A Mouse monoclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with PE.

Description: A Rabbit polyclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with PE.

Description: A Mouse monoclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with APC-Cy7.

Description: A Rabbit polyclonal antibody against Human Tumor Protein P63 (TP63). This antibody is labeled with APC-Cy7.

Description: A competitive ELISA for quantitative measurement of Human Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Human Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Human Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Goat Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Goat Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Goat Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rabbit Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rabbit Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rabbit Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Mouse Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Mouse Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Mouse Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Canine Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Canine Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Canine Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Monkey Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Monkey Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Monkey Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rat Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rat Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Rat Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Porcine Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Porcine Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Porcine Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: Recombinant Human Tumor protein 63(TP63) expressed in E.coli

Description: Quantitative sandwich ELISA for measuring Human Tumor protein 63 (TP63) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Tumor protein 63 (TP63) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Tumor protein 63 (TP63) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: A competitive ELISA for quantitative measurement of Guinea pig Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Guinea pig Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: A competitive ELISA for quantitative measurement of Guinea pig Tumor Protein P63 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. [UniProt]

Description: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. [UniProt]

Description: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. [UniProt]

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/1786), 1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against p63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2427), CF568 conjugate, Concentration: 0.1mg/mL